Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp18202_8k.htm |
Exhibit
99.01
|
Press
Release
|
 |
|
www.shire.com
|
Two
New Board Directors Appointed
Non-Executives
to join Shire’s Science &Technology and Remuneration Committees
Dublin, Ireland – June 17,
2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces that Dr David Ginsburg and Ms Anne Minto
OBE, have been appointed to the Shire Board of Directors with immediate
effect.
Dr
Ginsburg, MD is currently Professor of Internal Medicine & Human Genetics at
the Life Sciences Institute, University of Michigan; an Investigator at the
Howard Hughes Medical Institute and the Warner-Lambert/Parke-Davis Professor of
Medicine.
Dr
Ginsburg qualified at Yale University and has a very distinguished background
that includes many research achievements, fellowships, awards and published
papers. These have included a research post at Harvard Medical School and
numerous senior professorial positions across a broad spectrum of medical
specializms at the University of Michigan. Dr Ginsburg has also been
appointed to Shire’s Science & Technology Committee.
Anne Minto is Group
Director Human Resources at Centrica plc, a FTSE 30 integrated energy company
operating in the UK and US. Ms Minto qualified as a lawyer at Aberdeen
University and has an impressive business career that includes senior roles at
Shell UK and Smiths Group plc and the position of deputy director-general of the
Engineering Employers’ Federation.
Ms
Minto is a Fellow of both the Chartered Institute of Personnel & Development
and the London City and Guilds and a Member of Law Society of Scotland.
Anne Minto has also been appointed to Shire’s Remuneration Committee and she
will assume the Chair of that Committee on the retirement of Kate Nealon from
the Shire Board at the end of Ms Nealon’s term of office at the end of
July.
Shire Chairman,
Matthew Emmens commented: “I am very pleased that we have attracted two
highly qualified and experienced Directors to our Board. David’s medical
background and areas of specializm and Anne’s legal, commercial and remuneration
experience will be welcome additions to our strong team. I’d like to thank
Kate Nealon for her four years of service to Shire’s Board and for her
contributions to the Remuneration Committee.”
There is no further
information that is required to be disclosed under 9.6.13R of the United Kingdom
listing rules
For
further information please contact:
|
Investor
Relations
|
Cléa
Rosenfeld (Rest of the World)
|
+44 1256 894
160
|
|
Eric Rojas
(North America)
|
+1 781 482
0999
|
|
|
Media
|
Jessica Mann
(Rest of the World)
|
+44 1256 894
280
|
|
Matthew
Cabrey (North America, Specialty Pharma)
|
+1 484 595
8248
|
Notes
to editors
SHIRE
PLC
Shire’s strategic
goal is to become the leading specialty biopharmaceutical company that focuses
on meeting the needs of the specialist physician. Shire focuses its
business on attention deficit hyperactivity disorder (ADHD), human genetic
therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in
other therapeutic areas to the extent they arise through
acquisitions. Shire’s in-licensing, merger and acquisition efforts
are focused on products in specialist markets with strong intellectual property
protection and global rights. Shire believes that a carefully
selected and balanced portfolio of products with strategically aligned and
relatively small-scale sales forces will deliver strong results.
For further
information on Shire, please visit the Company’s website: www.shire.com.
"SAFE
HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995
Statements included
herein that are not historical facts are forward-looking statements. Such
forward-looking statements involve a number of risks and uncertainties and are
subject to change at any time. In the event such risks or uncertainties
materialize, the Company’s results could be materially adversely affected. The
risks and uncertainties include, but are not limited to, risks associated with:
the inherent uncertainty of research, development, approval, reimbursement,
manufacturing and commercialization of the Company’s Specialty Pharmaceutical
and Human Genetic Therapies products, as well as the ability to secure and
integrate new products for commercialization and/or development; government
regulation of the Company’s products; the Company’s ability to manufacture its
products in sufficient quantities to meet demand; the impact of competitive
therapies on the Company’s products; the Company’s ability to register, maintain
and enforce patents and other intellectual property rights relating to its
products; the Company’s ability to obtain and maintain government and other
third-party reimbursement for its products; and other risks and uncertainties
detailed from time to time in the Company’s filings with the Securities and
Exchange Commission.